Press Releases and Multimedia Coverage
PRESS RELEASES
May 12, 2025
DELFI Diagnostics CTO Recognized among 2025 Most Influential Women in Bay Area Business
April 25, 2025
DELFI Diagnostics to Present Early Detection and Advanced Cancer Monitoring Technology Updates at AACR Annual Meeting
January 8, 2025
DELFI Diagnostics to Participate in J.P. Morgan Healthcare Conference
December 2, 2024
DELFI Diagnostics Names Dr. Amoolya Singh as Chief Technology Officer
November 19, 2024
DELFI Diagnostics Selects Lahey Hospital & Medical Center to Administer New Lung Cancer Screening Test
October 29, 2024
DELFI Diagnostics Names Robert Guigley as Chief Commercial Officer to Expand Access to Early Cancer Screening
October 28, 2024
DELFI Diagnostics Working with Incendia Therapeutics to Employ Advanced Treatment Monitoring Test in a Phase 1 Clinical Trial
October 21, 2024
DELFI Diagnostics Study on Cancer Treatment Monitoring Using Fragmentomes Featured in Nature Communications
October 7, 2024
AHN explores use of promising new blood-based test to enhance lung cancer detection
August 26, 2024
DELFI Diagnostics Appoints Thomas Russo as Chief Financial Officer
June 11, 2024
Indigenous Pact and DELFI Diagnostics Join Forces to Enhance Lung Cancer Screening in Tribal Communities
June 3, 2024
Landmark Blood-Based AI Lung Cancer Screening Test Study Results Published in Cancer Discovery
May 13, 2024
OSF HealthCare and DELFI Diagnostics Announce Collaboration to Improve Lung Cancer Screening Rates
April 1, 2024
DELFI Diagnostics to Present at American Association for Cancer Research Annual Meeting
February 1, 2024
DELFI Diagnostics Announces Availability of New Fragmentome-Based Cancer Treatment Monitoring Assay
January 5, 2024
DELFI Diagnostics Appoints Susan Tousi as New Chief Executive Officer
December 13, 2023
DELFI Diagnostics Supports Proposed Legislation to Allow CMS to Review New Blood-Based Screening Tests for Lung Cancer
October 9, 2023
DELFI Diagnostics Launches FirstLook Lung, an Accessible, Accurate New Way to Enhance Lung Cancer Screening Through a Routine Blood Test
October 4, 2023
DELFI Diagnostics to Highlight Breakthrough Technology and Completed Clinical Study in Lung Cancer Detection
June 1, 2023
DELFI Diagnostics Hires David Morgenstern, PhD, as Vice President of Clinical Development
April 18, 2023
DELFI Diagnostics Presents Additional Promising Proof-of-Concept Data on its Monitoring Program at AACR 2023
February 23, 2023
DELFI Promotes Jenn Buechel to President and Chief Operating Officer
February 16, 2023
DELFI Hires Lee-Ann Smith-Freeman as Vice President of Legal
November 18, 2022
Positive Liver Cancer Detection Data Published in Cancer Discovery Shows Further Promise of Delfi’s AI Liquid Biopsy Platform
October 27, 2022
Researchers to Present Proof-of-Concept Liver Cancer Detection Data Using the DELFI Platform at AASLD The Liver Meeting® 2022
September 12, 2022
DELFI Diagnostics Selected as the Liquid Biopsy Partner for 4-IN-THE-LUNG-RUN: A Large-Scale European Lung Cancer Screening Study
August 23, 2022
DELFI Diagnostics Adds Finance and Market Access Leadership as it Prepares for Commercial Launch
July 18, 2022
DELFI Diagnostics Announces $225M Series B Financing
July 12, 2022
Jessica Meng Joins DELFI Diagnostics as Chief Commercial Officer
June 22, 2022
DELFI Diagnostics Appoints Jacob Van Naarden to its Board of Directors
May 17, 2022
DELFI Diagnostics Enters into Broad Research Agreement with Top U.S. Cancer Center
May 9, 2022
DELFI Diagnostics Initiates 15,000-Patient Prospective Lung Cancer Screening Trial
April 4, 2022
DELFI Researchers and Founders to Present at American Association for Cancer Research (AACR) 2022 Annual Meeting
March 30, 2022
DELFI Diagnostics Appoints Liz Homans to its Board of Directors
March 24, 2022
DELFI Diagnostics Adds Reimbursement, Regulatory Leaders to Management Team
October 21, 2021
DELFI Bolsters Leadership Team with Three Key Hires
October 7, 2021
Doug Schenkel Joins DELFI Diagnostics as Chief Financial Officer
August 20, 2021
DELFI Liquid Biopsy Shows Promise for Reducing Lung Cancer Deaths
June 23, 2021
Dr. Peter Bach Joins DELFI Diagnostics as Chief Medical Officer
March 31, 2021
DELFI Diagnostics Begins Enrollment for Prospective Lung Cancer Screening Trial Ahead of Planned Commercial Test
February 17, 2021
Industry Leaders Tara Maddala and Allison Ryan Join DELFI Diagnostics Leadership Team
January 12, 2021
DELFI Diagnostics Announces $100 Million Series A Financing to Develop a New Class of Early Detection Liquid Biopsy for Multiple Cancers
MULTIMEDIA COVERAGE
25 News Now
May 15, 2025
OSF HealthCare: Lung Cancer Screenings
San Francisco Business Times
May 15, 2025
How DELFI Diagnostics plans to make liquid biopsies more accessible
San Francisco Business Times
May 12, 2025
San Francisco Business Times Influential Women: Amoolya Singh, DELFI Diagnostics
Becker's Healthcare Podcast
April 27, 2025
How OSF Is Transforming Lung Cancer Screening with Innovative Blood Testing: Insights from Dr. Mark Meeker
Congressman Vern Buchanan
February 19, 2025
Buchanan Introduces Bills to Expand Access to Telehealth and Critical Lung Cancer Screenings
Mendelspod
February 6, 2025
Early Detection for Lung Cancer with Susan Tousi, DELFI Diagnostics
Channel 11 News
January 27, 2025
Allegheny Health Network Pilot Program Screens Lung Cancer Risk Through Blood Test
Medical Frontiers
January 6, 2025
Voice of Pittsburgh Interview with Dr. Ali Zaidi about FirstLook Lung
Observer-Reporter
December 13, 2024
Could a blood test detect lung cancer?
25 News Now
November 21, 2024
OSF HealthCare First Look Screenings
Pittsburgh Magazine
November 18, 2024
This Blood Test Can Help to Detect Whether or Not You Have Lung Cancer
Meeting You Where You're At Podcast
November 14, 2024
Episode 98: Susan Tousi - Stories from hlth.2024
Medical Laboratory Observer (MLO)
November 8, 2024
Peter Bach, MD, Chief Medical Officer of DELFI Diagnostics discusses blood test for lung cancer detection
MedCity News
November 3, 2024
Earlier Detection and Treatment are Essential for Meeting VBC Goals
The Doctor Podcast
November 1, 2024
Lung Cancer Screening Advances with Peter Bach, M.D.
Illumina Ventures
October 29, 2024
Spotlight on Susan Tousi – CEO DELFI Diagnostics
Genome Web
October 29, 2024
DELFI Diagnostics: Robert Guigley
Radiology Business
October 23, 2024
RadNet, American Lung Association launch ‘revolutionary’ cancer screening program
Biospace
October 22, 2024
DELFI Diagnostics Study on Cancer Treatment Monitoring Using Fragmentomes Featured in Nature Communications
360 Dx
August 26, 2024
DELFI Diagnostics: Thomas Russo
Precision Medicine Online
June 21, 2024
Delfi, Indigenous Pact Using Blood Test to Improve Lung Cancer Early Detection in Native Communities
Yahoo Finance
June 7, 2024
Johns Hopkins announces new blood test for early lung cancer detection
Stat
June 3, 2024
Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer
Los Angeles Daily News
May 31, 2024
City of Hope’s new blood test for lung cancer will mean more early detections
Chicago Tribune
May 10, 2024
A blood test to help detect lung cancer? New test offered at OSF Healthcare part of trend in medicine
The White House
May 1, 2024
FACT SHEET: As Part of the Inaugural National Cancer Prevention and Early Detection Month, Biden Cancer Moonshot Announces New Actions to Strengthen Preventive Cancer Care and Expand Accessibility of Cancer Screenings
OSF Healthcare Accelerated Podcast
April 23, 2024
Episode 31 - Take a Deep Breath Interview with Dr. Mark Meeker and Susan Tousi, CEO of DELFI Diagnostics
Washington Post
April 16, 2024
A blood test to detect cancer? Some patients are using them already
Precision Medicine Online
April 10, 2024
Delfi Diagnostics' Liquid Biopsy Technology Shows Promise for Ovarian Cancer Screening
US News & World Report
April 10, 2024
AI May Bring a Better Blood Test for Ovarian Cancer
GenomeWeb
April 2, 2024
City of Hope and DELFI Diagnostics announce collaboration to improve lung cancer screening rates in underserved areas of Los Angeles
GenomeWeb
March 15, 2024
Johns Hopkins Team Debuts New Method for Genome-Wide Detection of Cancer-Linked Repeat Sequences
Medium
February 17, 2024
Victor Velculescu, DELFI Diagnostics — Founder Story
Pharmexec
February 1, 2024
DELFI Diagnostics Launches Assay That May Improve Monitoring of Cancer Treatment Response
FierceBiotech
February 1, 2024
Delfi launches cancer-monitoring blood test alongside Immunocore collab
MedTech Dive
January 9, 2024
Susan Tousi leaves Illumina to become CEO of liquid biopsy firm Delfi
Baltimore Business Journal
January 5, 2024
Baltimore biotech backed by more than $300M in funding names new CEO
BNN Breaking
January 4, 2024
Susan Tousi, Illumina CCO, to Helm Delfi Diagnostics as New CEO
STAT
January 4, 2024
Illumina chief commercial officer leaves to lead liquid biopsy startup Delfi
Endpoints
January 4, 2024
Updated: Delfi Diagnostics hires Illumina’s chief commercial officer as next CEO
The Cancer Letter
November 17, 2023
Liquid biopsy cancer screening: We’ll need more than one size to fit all
MedTech Strategist
November 14, 2023
Can Delfi Diagnostics Fragmentomics be the key to detecting cancer early?
The Cancer Letter
October 13, 2023
Delfi Diagnostics Commercializes Blood Test for Lung Cancer Screening
Medical Device Network
October 10, 2023
DELFI Diagnostics introduces FirstLook Lung blood test
STAT
October 10, 2023
The Readout: Want a biotech buyout? Target cancer
MedTech Dive
October 9, 2023
Delfi launches lung cancer blood test based on DNA fragmentation
FierceBiotech
October 9, 2023
Delfi Diagnostics launches blood-based lung cancer screening test
STAT
October 9, 2023
Delfi launches its blood test to screen for lung cancer – and reveals challenges for liquid biopsies
BioTech TV
October 9, 2023
Delfi Diagnostics' team on launching the FirstLook Lung cancer blood screening test at #HLTH2023
360DX
September 26, 2023
BioAffinity Aims to Make Lung Cancer Test Available Nationally Following Pathology Lab Acquisition
STAT News
September 7, 2023
What a viral study criticizing cancer screening gets very, very wrong
GenomeWeb
August 22, 2023
DELFI Diagnostics Boost Lung Cancer Detection Power with Addition of Mutation Profiles DELFI Diagnostics Boost Lung Cancer Detection Power with Addition of Mutation Profiles
NCI Cancer Currents Blog
May 15, 2023
Can the New “Omics” on the Block Find Liver Cancer in Blood?
Baltimore Business Journal
May 12, 2023
Raising Baltimore’s Capital
STAT News
May 4, 2023
‘Are we better off with the information?’: Experts spar over the benefits of liquid biopsy to catch cancer
The Baltimore Sun
January 29, 2023
Baltimore researchers say AI could help reduce disparities, improve access in health care
Baltimore Business Journal
October 7, 2022
Leaders in Health Care 2022: Dr. Victor Velculescu, Delfi Diagnostics
Business Insider
September 6, 2022
21 Most Promising Health Tech Startups According to VCs 2022
San Francisco Business Times
August 30, 2022
Early-cancer detection company takes on billion-dollar competitors
Wall Street Journal
July 18, 2022
Delfi Diagnostics Gathers $225M for Cancer Blood Tests
GenomeWeb
May 17, 2022
Delfi Diagnostics, Memorial Sloan Kettering Partner to Advance Cancer Screening Technology
Precision Oncology News
May 9, 2022
Delfi Diagnostics Begins Second, Larger Prospective Lung Cancer Screening Trial
Fierce Biotech
March 7, 2022
Fierce Medtech’s 2021 Fierce 15
Fierce Biotech
August 20, 2021
Delfi Diagnostics’ AI-based blood test detects 80% of early-stage lung cancer cases, study finds
Stat News
June 23, 2021
Peter Bach, Industry Critic, Joins Company Aiming to Make Blood Tests to Detect Cancer
GenomeWeb
March 31, 2021
Delfi Diagnostics Starts Prospective Lung Cancer Screening Trial
FierceBiotech
January 13, 2021
Delfi Diagnostics Raises $100M for a New Approach to Screening Blood for Cancer
GenomeWeb
February 5, 2020
Methylation, Fragmentation Analyses Remain at Forefront of Early Detection Liquid Biopsy Development